細(xì)胞名稱：人肝癌細(xì)胞HepaRG

　　產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2

　　細(xì)胞數(shù)量：1x10^6；1x10^6

　　保存溫度：37℃；-198℃

　　運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸

　　安全等級(jí)：1

　　用途限制：僅供科研2類

　　培養(yǎng)體系：90%DMEM+10%FBS+1%三抗

　　培養(yǎng)溫度：37℃

　　二氧化碳濃度：5%

　　簡(jiǎn)介：人肝癌細(xì)胞HepaRG取自女性供體，貼壁培養(yǎng)。

　　注釋：Registration:International Depositary Authority,Pasteur Institute Collection Nationale de Cultures de Micro-organismes(CNCM);I-2652.

　　Characteristics:Can be induced to differentiate into hepatocyte-like cells by exposure to DMSO.

　　Characteristics:Cell line main applications are sugar and lipid metabolism,physiopathology;drug metabolism and toxicology and viral infection.

　　Omics:Deep proteome analysis.

　　Omics:Membrane proteome analysis.

　　Omics:miRNA expression profiling.

　　Omics:Transcriptome analysis.

　　Anecdotal:The'RG'in the cell name stands for Rumin and Gripon,the two scientists that were influential in the establishment of this cell line.

　　基因突變：/

　　HLA信息：/

　　STR信息：/

　　參考文獻(xiàn)：PubMed=12432097;DOI=10.1073/pnas.232137699

　　Gripon P.,Rumin S.,Urban S.,Le Seyec J.,Glaise D.,Cannie I.,Guyomard C.,Lucas J.,Trepo C.,Guguen-Guillouzo C.

　　Infection of a human hepatoma cell line by hepatitis B virus.

　　Proc.Natl.Acad.Sci.U.S.A.99:15655-15660(2002)

　　PubMed=17241619;DOI=10.1016/j.cbi.2006.12.003

　　Guillouzo A.,Corlu A.,Aninat C.,Glaise D.,Morel F.,Guguen-Guillouzo C.

　　The human hepatoma HepaRG cells:a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.

　　Chem.Biol.Interact.168:66-73(2007)

　　PubMed=17393521;DOI=10.1002/hep.21536

　　Cerec V.,Glaise D.,Garnier D.,Morosan S.,Turlin B.,Drenou B.,Gripon P.,Kremsdorf D.,Guguen-Guillouzo C.,Corlu A.

　　Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor.

　　Hepatology 45:957-967(2007)

　　Patent=US7456018

　　Gripon P.,Guguen-Guillouzo C.,Trepo C.,Rumin S.

　　Human hepatoma lines,methods for obtaining same and uses thereof.

　　Patent number US7456018,25-Nov-2008

　　PubMed=20228232;DOI=10.1124/dmd.109.031831

　　Hart S.N.,Li Y.,Nakamoto K.,Subileau E.-A.,Steen D.,Zhong X.-B.

　　A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

　　Drug Metab.Dispos.38:988-994(2010)

　　PubMed=20645056;DOI=10.1007/978-1-60761-688-7_13

　　Marion M.-J.,Hantz O.,Durantel D.

　　The HepaRG cell line:biological properties and relevance as a tool for cell biology,drug metabolism,and virology studies.

　　Methods Mol.Biol.640:261-272(2010)

　　PubMed=21414303;DOI=10.1016/j.bcp.2011.03.004

　　Ceelen L.,De Spiegelaere W.,David M.,De Craene J.,Vinken M.,Vanhaecke T.,Rogiers V.

　　Critical selection of reliable reference genes for gene expression study in the HepaRG cell line.

　　Biochem.Pharmacol.81:1255-1261(2011)

　　PubMed=22568886;DOI=10.1517/17425255.2012.685159

　　Andersson T.B.,Kanebratt K.P.,Kenna J.G.

　　The HepaRG cell line:a unique in vitro tool for understanding drug metabolism and toxicology in human.

　　Expert Opin.Drug Metab.Toxicol.8:909-920(2012)

　　PubMed=22594799;DOI=10.3109/13813455.2012.683442

　　Samanez C.H.,Caron S.,Briand O.,Dehondt H.,Duplan I.,Kuipers F.,Hennuyer N.,Clavey V.,Staels B.

　　The human hepatocyte cell lines IHH and HepaRG:models to study glucose,lipid and lipoprotein metabolism.

　　Arch.Physiol.Biochem.118:102-111(2012)

　　PubMed=22643240;DOI=10.1016/j.tiv.2012.05.008

　　Antherieu S.,Chesne C.,Li R.,Guguen-Guillouzo C.,Guillouzo A.

　　Optimization of the HepaRG cell model for drug metabolism and toxicity studies.

　　Toxicol.In Vitro 26:1278-1285(2012)

　　PubMed=22857383;DOI=10.1186/1477-5956-10-47

　　Sokolowska I.,Dorobantu C.,Woods A.G.,Macovei A.,Branza-Nichita N.,Darie C.C.

　　Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells.

　　Proteome Sci.10:47-47(2012)

　　PubMed=23887712;DOI=10.1038/ncomms3218

　　Nault J.-C.,Mallet M.,Pilati C.,Calderaro J.,Bioulac-Sage P.,Laurent C.,Laurent A.,Cherqui D.,Balabaud C.,Zucman-Rossi J.

　　High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

mun.4:2218-2218(2013)

　　PubMed=26160117;DOI=10.1093/toxsciv136

　　Sison-Young R.L.C.,Mitsa D.,Jenkins R.E.,Mottram D.,Alexandre E.,Richert L.,Aerts H.,Weaver R.J.,Jones R.P.,Johann E.,Hewitt P.G.,Ingelman-Sundberg M.,Goldring C.E.P.,Kitteringham N.R.,Park B.K.

parative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition,bioactivation,and detoxication.

　　Toxicol.Sci.147:412-424(2015)

　　PubMed=26694163;DOI=10.1371/journal.pone.0144924

　　Janiszewska J.,Szaumkessel M.,Kostrzewska-Poczekaj M.,Bednarek K.,Paczkowska J.,Jackowska J.,Grenman R.,Szyfter K.,Wierzbicka M.,Giefing M.,Jarmuz-Szymczak M.

　　Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma.

　　PLoS ONE 10:E0144924-E0144924(2015)

　　PubMed=27169750;DOI=10.1038ep24709

　　Sharanek A.,Burban A.,Burbank M.,Le Guevel R.,Li R.,Guillouzo A.,Guguen-Guillouzo C.

　　Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.

　　Sci.Rep.6:24709-24709(2016)

　　PubMed=27780834;DOI=10.1124/dmd.116.072603

　　van der Mark V.A.,de Waart D.R.,Shevchenko V.,Oude Elferink R.P.J.,Chamuleau R.A.F.M.,Hoekstra R.

　　Drug Metab.Dispos.45:56-67(2017)

　　PubMed=27975304;DOI=10.1007/978-1-4939-6700-1_2

　　Ni Y.,Urban S.

　　Hepatitis B virus infection of HepaRG cells,HepaRG-hNTCP cells,and primary human hepatocytes.

　　Methods Mol.Biol.1540:15-25(2017)

　　PubMed=28904299;DOI=10.2131/jts.42.641

　　Tomida T.,Ishimura M.,Iwaki M.

　　A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis.

　　J.Toxicol.Sci.42:641-650(2017)</a>

查看全部介紹